Health and Healthcare

All Health and Healthcare Articles

Newest first · Page 351

IPO FILING: AutoGenomics Inc.

Apparently the IPO filing hiatus isn’t entirely a dead end story.  A company called AutoGenomics, Inc. has filed a registration statement for a proposed initial public offering.  It has applied for the ticker "AGMX"…

Douglas A. McIntyre · 18 years ago

GE Makes a Health Care Acquisition (GE, VITL)

Vital Signs Inc. (NASDAQ: VITL) is going to gap way up this morning. The company is being acquired by General Electric Co. for $860 million in cash, which comes to $74.50 per share. Vital…

Douglas A. McIntyre · 18 years ago

Genentech & Roche Merger Coming Under More Fire (DNA)

Genentech Inc. (NYSE: DNA) is running into some issues over the merger with Roche at $89.00 per share.  Wall Street DOES expect this merger to close with Genentech becoming a subsidiary again rather than…

Douglas A. McIntyre · 18 years ago

State Street International Health Care ETF Launch (STT, IRY)

State Street Corporation (NYSE: STT) has announced that its State Street Global Advisors unit is launching 10 new SPDR exchange-traded funds, which are supposed to begin trading on the American Stock Exchange today. SPDR(R)…

Douglas A. McIntyre · 18 years ago

Merck Visits The Proctologist (MRK)

Merck & Co. (NYSE: MRK) posted earnings that look pretty good on the surface.  The problem is that the surface is about the only thing that looked appealing for the drug giant today. Merck…

Douglas A. McIntyre · 18 years ago

ERBITUX Gets Approved in Japan for Colorectal Cancer (IMCL, BMY)

ImClone Systems Incorporated (NASDAQ: IMCL) has just announced that ERBITUX(R) has received marketing authorization in Japan for use in treating patients with advanced or metastatic colorectal cancer (mCRC). This approval will allow the use…

Douglas A. McIntyre · 18 years ago

Genentech Masks a Whiff (DNA)

Genentech Inc. (NYSE: DNA) is initially looking like a severe disappointment to those who thought Cramer’s call last week was the right one.  The largest biotech in the U.S. posted $0.82 EPS on $3.23…

Douglas A. McIntyre · 18 years ago

Genentech Ready to Lead Biotech Earnings Bias (DNA, BIIB)

Genentech Inc. (NYSE: DNA) is set to report earnings after the close of trading today.  The largest biotech in the U.S. is expected to post $0.86 EPS on $3.23 Billion in revenues according to…

Douglas A. McIntyre · 18 years ago

Long-Term Risks To Statin Sales? (MRK, PFE, AZN)

We have run a full feature story over at BioHealthInvestor.com after reading a study that came off the Mayo Clinic site.  The study showed that a combination of fish oil and red rice yeast…

Douglas A. McIntyre · 18 years ago

This Week’s BioHealth & Biotech Top Stories

We saw another exciting week full of news for key developments in drug stocks, biotech stocks, medical device stocks, and other companies involved in various aspects of health care and medicine.  Below are some…

Douglas A. McIntyre · 18 years ago

IPO FILING: ZONARE MEDICAL SYSTEMS (ZONE)

ZONARE MEDICAL SYSTEMS, INC. has filed for an initial public offering to sell up to $86.25 million as the nominal securities amount.  The company has applied to take on the stock ticker of "ZONE"…

Douglas A. McIntyre · 18 years ago

IPO FILING: Alimera Sciences, Inc. (ALIM)

A company called Alimera Sciences, Inc. has filed for an initial public offering to sell up to $75 million as the nominal securities amount.  The company noted that all shares will be sold by…

Douglas A. McIntyre · 18 years ago

UnitedHealth Guidance Tanks Again (UNH)

UnitedHealth Group (NYSE:UNH) is again lowering its guidance.  The company now sees $2.95 to $3.05 EPS on revenues of around $81 Billion range.  Its prior guidance was $3.55 to $3.60.  First Call has estimates…

Douglas A. McIntyre · 18 years ago

The Whining From Drug Companies: The FDA Is Hard On Us

The profit-mongering Big Pharma companies don’t want the FDA to take so long approving their drugs. It cuts into profits and delays their chances of making money on new blockbuster treatments. According to The…

Douglas A. McIntyre · 18 years ago